Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 16, 2007

Progen Employs Quintiles to Assist with Phase III Trial of Oncology Therapy

  • Progen Pharmaceuticals (www.progen. com.au) will use Quintiles’ (www.quintiles.com) services for clinical development-related projects. This agreement includes the execution of the Phase III trial of anticancer drug PI-88 for the treatment of primary liver cancer (hepatocellular carcinoma). Progen says that it is on track to initiate recruitment in the fourth quarter of 2007.


Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »